A proatherogenic role for C-reactive protein in vivo

Current Opinion in Lipidology

Volumn 16, Issue 5, 2005, Pages 512-517

  Paul, Antoni ^a   Yeh, Edward T H ^b   Chan, Lawrence ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Atherosclerosis; C reactive protein; Complement; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ANAPHYLATOXIN; ANGIOTENSIN ANTAGONIST; C REACTIVE PROTEIN; CD40 LIGAND; CHEMOATTRACTANT; CHEMOKINE RECEPTOR CCR2; FC RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; OPSONIN; RECOMBINANT PROTEIN;

AMINO TERMINAL SEQUENCE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOLOGICAL ACTIVITY; COMPLEMENT ACTIVATION; DISEASE SEVERITY; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; HUMAN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STABLE ANGINA PECTORIS; VASCULAR SMOOTH MUSCLE;

EID: 25444451095     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mol.0000180164.70077.a7     Document Type: Review

References (45)

1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126.
3. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565.
4. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 279: 48487-48490.
5. Danesh J, Wheeler JG, Hirschfield GM, et al. C-Reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
6. Paul A, Ko KWS, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 2004; 109: 647-655.
7. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-1812.
8. Oksjoki R, Kovanen PT, Pentikainen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003; 14:477-482.
9. Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C- reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974; 112:2135-2147.
10. Siegel J, Rent R, Gewurz H. Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera. J Exp Med 1974; 140:631-647.
11. Mold C, Gewurz H, Du Clos TW. Regulation of complement activation by C-reactive protein. Immunopharmacology 1999; 42:23-30.
12. Jarva H, Jokiranta TS, Hellwage J, et al. Regulation of complement activation by C-reactive protein: targeting the complement inhibitory activity of factor H by an interaction with short consensus repeat domains 7 and 8-11. J Immunol 1999; 163:3957-3962.
13. Alving CR, Richards RL, Guirguis AA. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. J Immunol 1977; 118:342-347.
14. Seifert PS, Hugo F, Tranum-Jensen J, et al. Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 172:547-557.
15. Bhakdi S, Torzewski M, Paprotka K, et al. Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence. Circulation 2004; 109:1870-1876. This paper compares the activation of the complement system by enzymatically remodeled LDL in the presence and absence of CRP. It reports that binding of CRP to enzymatically remodeled LDL triggers complement activation faster, but the resulting complement activation halts before the terminal cascade. The data also show a lack of complement-activating capacity by native and oxidized LDL.
16. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000; 192:1353-1364.
17. Chang MK, Binder CJ, Torzewski M, Witztum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 2002; 99:13043-13048.
18. Taskinen S, Hyvonen M, Kovanen PT, et al. C-reactive protein binds to the 3beta-OH group of cholesterol in LDL particles. Biochem Biophys Res Commun 2005; 329:1208-1216. This study showed that CRP can bind cholesterol in LDL particles and the interaction is mediated by the phosphorylcholine-binding site of CRP and the 3-β-OH group of cholesterol.
19. Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386:292-296.
20. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105:1049-1056.
21. Smith JD. An A+ for macrophages in reducing atherosclerosis? Arterioscler Thromb Vasc Biol 2001; 21:1710-1711.
22. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003; 108:512-515.
23. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 2004; 36:405-410. This paper showed that CRP induces IL-8 synthesis and secretion in human aortic endothelial cells via the upregulation of nuclear factor kappa B activity.
24. Kibayashi E, Urakaze M, Kobashi C, et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci (Lond) 2005; 108:515-521. CRP induces the production of IL-8 and pivastatin (an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase) inhibits this effect.
25. Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103:2531-2534.
26. Han KH, Hong KH, Park JH, et al. C-reactive protein promotes monocyte chemoattractant protein-1-mediated chemotaxis through upregulating CC chemokine receptor 2 expression in human monocytes. Circulation 2004; 109:2566-2571. This study showed that elevated blood CRP levels may promote the accumulation of monocytes in atherosclerotic lesions by increasing the response to MCP-1.
27. Lin R, Liu J, Gan W, Yang G. C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells. Biol Pharm Bull 2004; 27:1537-1543. The data reported in this paper support the proinflammatory effects of CRP via the CD40-CD40 ligand signaling pathway. The effect of CRP can be attenuated by lovastatin and fenofibrate.
28. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001; 58:4-43.
29. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A 2000; 97:6930-6932.
30. Blaschke F, Bruemmer D, Yin F, et al. C-reactive protein induces apoptosis in human coronary vascular smooth muscle cells. Circulation 2004; 110:579-587. This study showed that GADD153 is a CRP-regulated gene in human vascular smooth muscle cells and plays a causal role in CRP-induced apoptosis.
31. Prasad K. C-reactive protein increases oxygen radical generation by neutrophils. J Cardiovasc Pharmacol Ther 2004; 9:203-209. This paper showed that CRP-induced atherosclerosis may be mediated through the generation of oxygen radicals by neutrophils.
32. van den Berg CW, Taylor KE, Lang D. C-reactive protein-induced in vitro vasorelaxation is an artefact caused by the presence of sodium azide in commercial preparations. Arterioscler Thromb Vasc Biol 2004; 24:e168-e171. This report indicates that CRP has no vasorelaxant properties per se, and the reported vasorelaxant ability of CRP is an artifact caused by sodium azide.
33. Swafford AN Jr, Bratz IN, Knudson JD, et al. C-reactive protein does not relax vascular smooth muscle: effects mediated by sodium azide in commercially available preparations. Am J Physiol Heart Circ Physiol 2005; 288:H1786-H1795. Another paper that cautions that the acute vasoactive properties of commercially available CRP preparations may be attributable to sodium azide.
34. Bisoendial RJ, Kastelein JJP, Levels JHM, et al. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res 2005; 96:714-716. This study reported that CRP infusion induced a proinflammatory state as reflected by increases in plasma levels of IL-6 and IL-8. The plasma level of TNF-α remained unaltered. Coagulation activation was associated with increased prothrombin F1-2, D-dimer and PAI-1.
35. Clynes R, Maizes JS, Guinamard R, et al. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 1999; 189:179-185.
36. Mold C, Rodriguez W, Rodic-Polic B, Du Clos TW. C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol 2002; 169:7019-7025.
37. Pan LF, Kreisle RA, Shi YD. Detection of Fcgamma receptors on human endothelial cells stimulated with cytokines tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). Clin Exp Immunol 1998; 112:533-538.
38. Hakonarson H, Carter C, Kim C, Grunstein MM. Altered expression and action of the low-affinity IgE receptor FcepsilonRII (CD23) in asthmatic airway smooth muscle. J Allergy Clin Immunol 1999; 104:575-584.
39. Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovasc Res 2003; 58:186-195.
40. Jabs WJ,Theissing E, Nitschke M, et al. Local generation of C-reactive protein in diseased coronary artery venous bypass grafts and normal vascular tissue. Circulation 2003; 108:1428-1431.
41. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158:1039-1051.
42. Calabro P, Willerson JT, Yeh ETH. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108:1930-1932.
43. Ishikawa T, Hatakeyama K, Imamura T, et al. Involvement of C-reactive protein obtained by directional coronary atherectomy in plaque instability and developing restenosis in patients with stable or unstable angina pectoris. Am J Cardiol 2003; 91:287-292.
44. Sattler KJ, Woodrum JE, Galili O, et al. Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor kappaB activation and C-reactive protein expression in human carotid artery plaques. Stroke 2005; 36:14-20. The authors detected CRP mRNA within carotid artery plaques, suggesting that CRP is transcribed locally. The combined treatment with renin-angiotensin system blockers and acetylsalicylic acid reduced the expression of CRP within the atherosclerotic lesions.
45. Ishikawa T, Imamura T, Hatakeyama K, et al. Possible contribution of C-reactive protein within coronary plaque to increasing its own plasma levels across coronary circulation. Am J Cardiol 2004; 93:611-614. This study detected CRP mRNA in coronary plaques and showed that plasma CRP levels were significantly higher in the great cardiac vein than in the coronary artery. The increase in transcoronary CRP level was proportional to the severity of coronary artery disease.